本帖最后由 橙色雨丝 于 2016-5-24 09:44 编辑
标题:Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma
来源:JAMA. 2016 May 17(《美国医学会杂志》)
作者:Nabhan C等
This JAMA Clinical Guidelines Synopsis summarizes the National Comprehensive Cancer Network’s and European Society of Medical Oncology’s recent recommendations on follow-up imaging in patients in remission from Hodgkin and diffuse large B-cell lymphoma.
此JAMA临床指南概要总结了美国国家综合癌症网和欧洲临床肿瘤协会关于霍奇金和弥漫大B淋巴瘤病人在缓解期间影像学监测的最新建议。
Guideline title 指南标题 Follow-up Surveillance Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma Patients in Remission Without Clinical or Radiographic Evidence of Disease 处于缓解期的霍奇金和弥漫大B淋巴瘤病人在没有临床或者放射学疾病迹象情况下的影像学监测随访
Developers 编纂者 National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) 美国国家综合癌症网(NCCN)和欧洲临床肿瘤协会(ESMO)
Target population 适用人群 All patients with Hodgkin and diffuse large B-cell non-Hodgkin lymphomas who have completed initial therapy and are in complete remission 所有完成了初治并处于完全缓解的霍奇金和弥漫大B淋巴瘤病人
Major recommendations 建议要点 Once remission is confirmed in patients with Hodgkin lymphoma, imaging should be done as clinically indicated. No routine screening imaging is recommended. Surveillance positron emission tomography (PET) scans are not recommended. 对于霍奇金淋巴瘤病人,一旦缓解得到确认,影像学检查应在有临床指征时进行。不建议做常规的影像学筛查。不建议用PET做为监测手段。 Beyond 5 years, Hodgkin lymphoma patients with higher risk of lung cancer (prior radiation therapy to chest and/or prior use of alkylating agents) should undergo annual low-dose chest computed tomography (CT). 缓解5年后,具有较高肺癌风险的霍奇金病人(先前接受过胸部放疗和/或使用过烷化剂药物)应每年进行低剂量胸部CT检查。 Women with Hodgkin lymphoma and prior chest/axillary radiation should have yearly magnetic resonance imaging (MRI) or mammograms starting 8 to 10 years after therapy completion or at age 40 years, whichever comes first. 接受过胸部/腋窝放疗的女性霍奇金病人应在完成治疗8-10年后或者在40岁开始,无论哪个在前,每年进行核磁共振检查或乳房X光造影检查。 Imaging studies should be conducted only as clinically indicated (for abnormal laboratory results, atypical examination findings, or abnormal symptoms) for diffuse large B-cell lymphoma patients in remission (NCCN) or at a very low frequency (6, 12, and 24 months) only (ESMO). Surveillance PET scans are not recommended. 对于处于缓解期的弥漫大B病人,仅在具有临床指征(实验室指标异常,检查结果不典型,或异常症状)的情况下进行影像学检查(NCCN),或者进行很低频率(6,12和24个月)的影像学检查(ESMO)。
|